[go: up one dir, main page]

NO332265B1 - Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom - Google Patents

Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom Download PDF

Info

Publication number
NO332265B1
NO332265B1 NO20055305A NO20055305A NO332265B1 NO 332265 B1 NO332265 B1 NO 332265B1 NO 20055305 A NO20055305 A NO 20055305A NO 20055305 A NO20055305 A NO 20055305A NO 332265 B1 NO332265 B1 NO 332265B1
Authority
NO
Norway
Prior art keywords
alkyl
mmol
carboxylic acid
pyrrolo
pyridine
Prior art date
Application number
NO20055305A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055305L (no
NO20055305D0 (no
Inventor
Karen Lesley Schofield
Stuart Edward Bradley
Thomas Martin Krulle
Peter John Murray
Martin James Procter
Robert John Rowley
Colin Peter Sambrook Smith
Gerard Hugh Thomas
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of NO20055305D0 publication Critical patent/NO20055305D0/no
Publication of NO20055305L publication Critical patent/NO20055305L/no
Publication of NO332265B1 publication Critical patent/NO332265B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20055305A 2003-05-21 2005-11-10 Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom NO332265B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US55125604P 2004-03-08 2004-03-08
PCT/US2004/016243 WO2004104001A2 (en) 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase

Publications (3)

Publication Number Publication Date
NO20055305D0 NO20055305D0 (no) 2005-11-10
NO20055305L NO20055305L (no) 2005-12-15
NO332265B1 true NO332265B1 (no) 2012-08-13

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055305A NO332265B1 (no) 2003-05-21 2005-11-10 Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom

Country Status (16)

Country Link
EP (1) EP1636224B1 (uk)
JP (2) JP2006528702A (uk)
KR (1) KR101120935B1 (uk)
AT (1) ATE473974T1 (uk)
AU (1) AU2004240946B8 (uk)
BR (1) BRPI0410445B1 (uk)
CA (1) CA2525502C (uk)
DE (1) DE602004028122D1 (uk)
EA (1) EA009215B1 (uk)
IL (1) IL171851A (uk)
MA (1) MA27809A1 (uk)
MX (1) MXPA05012547A (uk)
NO (1) NO332265B1 (uk)
NZ (1) NZ543482A (uk)
UA (1) UA84146C2 (uk)
WO (1) WO2004104001A2 (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
TWI341835B (en) * 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
ATE483708T1 (de) * 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
EP1732566A4 (en) * 2004-04-05 2010-01-13 Takeda Pharmaceutical 6-azaindole COMPOUND
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
ES2324173T3 (es) 2004-12-02 2009-07-31 Prosidion Limited Amidas del acido pirrolopiridin-2-carboxilico.
PT1819704E (pt) 2004-12-02 2008-10-06 Prosidion Ltd Derivado amida de ácido pirrolopiridina-2-carboxílico útil como inibidor de glicogénio fosforilase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
CA2626190A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CN101331131A (zh) * 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2089017A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2835216A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
JP5959075B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
US9345247B2 (en) 2012-08-17 2016-05-24 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9A INHIBITOR
CN116507627B (zh) 2020-11-02 2026-01-23 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
JP2024509936A (ja) * 2021-03-10 2024-03-05 ビンシア・バイオサイエンシーズ・インコーポレイテッド Usp30阻害剤及びその使用
WO2023165168A1 (zh) * 2022-10-27 2023-09-07 常州大学 吡唑类衍生物作为β2肾上腺素受体别构调节剂,拮抗剂和激动剂的应用
CN115745891B (zh) * 2022-11-10 2025-08-01 常州大学 吡唑衍生物在作为β2-肾上腺素受体拮抗剂的应用
CN115894373B (zh) * 2022-10-27 2025-08-01 常州大学 N-取代苄基吡唑衍生物在作为β2肾上腺素受体调节剂、拮抗剂和激动剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
KR960703856A (ko) * 1994-06-06 1996-08-31 가와노 다케히코 축합 고리를 갖는 카르복실산 화합물, 이의 염 및 이의 약학적 용도(novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof)
CA2224062C (en) * 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
KR100241643B1 (ko) * 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
DE60334015D1 (de) * 2002-10-30 2010-10-14 Merck Frosst Canada Ltd Pyridopyrrolizin- und pyridoindolizinderivate

Also Published As

Publication number Publication date
MA27809A1 (fr) 2006-03-01
JP5669691B2 (ja) 2015-02-12
DE602004028122D1 (de) 2010-08-26
EP1636224B1 (en) 2010-07-14
NO20055305L (no) 2005-12-15
EA009215B1 (ru) 2007-12-28
IL171851A (en) 2011-08-31
AU2004240946B2 (en) 2011-09-08
JP2011252005A (ja) 2011-12-15
JP2006528702A (ja) 2006-12-21
AU2004240946A1 (en) 2004-12-02
BRPI0410445A (pt) 2006-05-30
WO2004104001A2 (en) 2004-12-02
AU2004240946B8 (en) 2012-01-12
NZ543482A (en) 2009-02-28
KR101120935B1 (ko) 2012-03-05
MXPA05012547A (es) 2006-05-25
WO2004104001A3 (en) 2005-03-03
KR20060069792A (ko) 2006-06-22
UA84146C2 (uk) 2008-09-25
EP1636224A2 (en) 2006-03-22
ATE473974T1 (de) 2010-07-15
NO20055305D0 (no) 2005-11-10
BRPI0410445B1 (pt) 2017-11-28
CA2525502C (en) 2012-12-18
EA200501645A1 (ru) 2006-06-30
CA2525502A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
NO332265B1 (no) Pyrrolopyridin-2-karboksylsyreamidinhibitorer, fremstilling av og mellomprodukter ved fremstilling av slike, preparater og kombinasjoner omfattende slike, slike forbindelser og preparater som medikament samt slike forbindelser for behandling av sykdom
KR102642203B1 (ko) 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
KR102564201B1 (ko) 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US8158622B2 (en) Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
TW202216679A (zh) 抗病毒化合物
IL275058B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
KR20240095318A (ko) 단백질분해 조절제 및 연관된 사용 방법
CA2608072A1 (en) Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
ES2348702T3 (es) Amidas de acidos pirrolopiridina-2-carboxilicos inhibidores de la glucogeno-fosforilasa.
US20240156780A1 (en) Tlr2 modulator compounds, pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees